Eilean Therapeutics to Showcase Novel MALT1 Degrader at ASH
Eilean Therapeutics LLC, an innovative biopharmaceutical firm, has confirmed that an abstract highlighting their first-of-its-kind oral MALT1 degrader will be presented as a poster at the influential American Society of Hematology (ASH) Annual Meeting. This prestigious event is set to take place in December, and Eilean aims to draw attention to their groundbreaking findings.
Abstract Overview: ZE66-0205 Development
The poster presentation will focus on the development of ZE66-0205, a cutting-edge MALT1 degrader designed to combat B-cell malignancies. The session, which falls under the theme of Molecular Pharmacology and Drug Resistance, signifies a critical opportunity for researchers and medical professionals to engage with the latest advancements in this promising area.
Poster Session Details
The abstract presentation will be featured in Session 605, specifically dedicated to lymphoid neoplasms. Participants can look forward to examining the innovative approaches that Eilean Therapeutics is taking to address significant challenges faced in treating these malignancies.
Key Presentation Information
Attendees should note the presentation is scheduled for Sunday during the ASH meeting, with the timing set for 6:00 PM to 8:00 PM. This two-hour window allows for in-depth discussion and interaction around the findings being shared.
About Eilean Therapeutics
Founded by partners including Orbimed and Torrey Pines Investment, along with renowned expert Dr. John C. Byrd, Eilean Therapeutics is dedicated to discovering and developing pioneering small molecule inhibitors. Their focus lies on targeting escape mutations prevalent in hematologic and solid tumors. The company utilizes a proprietary AI platform, integrating bold data from strategic partnerships to enhance their drug development processes.
Mission Statement
Eilean Therapeutics is on a mission to push the boundaries of innovation in medicine. By leveraging their unique capabilities, they aim to emerge as a frontrunner in delivering groundbreaking therapies, offering patients new hope in the battle against hematologic and other cancer types.
Media Inquiries
For further information regarding the presentation or the ongoing work at Eilean Therapeutics, media representatives and interested parties can reach out to Amy Burd, Chief Scientific Officer, who is available for queries concerning the company's activities and advancements.
Frequently Asked Questions
What is the significance of the MALT1 degrader in cancer treatment?
The MALT1 degrader represents a novel therapeutic approach that aims to target and inhibit specific mutations, providing potentially effective treatment options for patient populations with B-cell malignancies.
How can I attend the poster presentation at the ASH Annual Meeting?
The poster presentation will occur on Sunday during the ASH Annual Meeting; registration for the event would give access to attend and learn about these advancements.
Who are the partners involved in Eilean Therapeutics?
Eilean Therapeutics was co-founded by key players including Orbimed and Torrey Pines Investment, alongside esteemed oncologist Dr. John C. Byrd.
What types of cancers is Eilean Therapeutics focused on?
The company focuses on treating hematologic malignancies and solid tumors, employing innovative strategies to tackle escape mutations associated with these conditions.
How does Eilean Therapeutics utilize AI in its research?
The company applies a proprietary hybrid AI platform to streamline the discovery process, allowing for more precise targeting of molecular mechanisms related to cancer pathology.
